Vical Granted Six U.S. Patents for HSV-2 Vaccines SAN

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vical Granted Six U.S. Patents for HSV-2 Vaccines

SAN DIEGO, Oct. 8, 2014 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq: VICL ) announced today the issuance of six U.S. patents that provide broad coverage of DNA vaccines for herpes simplex virus type 2 (HSV-2), containing specific gene sequences and formulated with Vical's Vaxfectin ® adjuvant. These patents resulted from collaboration with the laboratories of leading HSV experts Drs. David Koelle and Lawrence Corey at the University of Washington under a multi-year NIH grant. The intellectual property is jointly owned by the University of Washington and Vical.

The new patents cover composition of matter of plasmid DNA vaccines encoding several HSV-2 antigens, including envelope and tegument viral proteins, separately or in combination, and formulated with Vical's Vaxfectin ® adjuvant. These new patents add to Vical's family of intellectual property that is based on the company's discovery that administering genetic sequences such as DNA or RNA into the body, without the use of viral delivery vehicles, will result in expression of the proteins encoded by the genetic sequences. Vical has additional issued patents covering the composition and use of its Vaxfectin ® adjuvant. The six recently issued HSV-2 U.S. patents are 8,828,408; 8,834,894; 8,840,903; 8,840,904; 8,852,610; and 8,852,611. Vical's five previously issued HSV-2 U.S. patents include 7,628,993; 7,879,339; 7,935,352; 8,263,087; and 8,293,248.

HSV-2 is a sexually transmitted virus that is the main cause of recurrent genital herpes, accounting for the majority of genital ulcerative lesions worldwide. Genital herpes is not only physically taxing (pain, itching and other morbidities), but also psychologically debilitating, especially given the fear of transmission. The CDC estimated the U.S. prevalence of HSV-2 to be 16% of 14- to 49-year-olds and the WHO estimated the global prevalence to be roughly 16% of people aged 15 to 49 years, or over 500 million. Only 10% to 25% of HSV-2-seropositive individuals are symptomatic and recognize their genital herpes infection.High unmet medical needs exist for new treatments because existing treatments of acyclovir-based antivirals can temporarily reduce but not eliminate genital herpes, viral shedding, and transmission; these drugs have not appreciably impacted HSV-2 seroprevalence rates despite over 30 years of usage. A therapeutic vaccine is a novel approach for treating genital herpes. Vical is currently testing its therapeutic HSV-2 DNA vaccine in a Phase 1/2 trial designed to reduce the frequency and magnitude of viral shedding and reduce genital lesion recurrences in HSV-2 positive subjects aged 18 to 50 years at seven U.S. clinical sites. This trial is proceeding according to plan, with ongoing enrollment and dosing of subjects in the efficacy cohort. Vical expects the trial to be fully enrolled in the fourth quarter of 2014, with topline data projected to be available in mid-2015. Further details about this trial can be found at ClinicalTrials.gov, NCT02030301.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases, in which the expressed protein is an immunogen; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com .

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the scope of coverage of and potential applications for Vical's patents, the potential uses and benefits of Vical's technologies and their potential application in vaccines against HSV-2 and whether the HSV-2 clinical trial will fully enroll. Risks and uncertainties include whether Vical's issued patents will be challenged and whether such challenges will have an adverse effect on the scope or validity of the patents; whether Vical will pursue enforcement of its issued patents or be successful in any such enforcement efforts; whether Vical will successfully prosecute additional patent applications and if so, whether such applications will lead to the issuance of additional patents; whether the clinical development efforts will result in a vaccine candidate that can generate immune responses sufficient to reduce or eliminate periodic viral flare-ups and the associated viral shedding and transmission; whether the Vaxfectin ® adjuvant will effectively enhance the performance of the HSV-2 vaccine; whether Vical or others will continue development of HSV-2 product candidates; whether Vical will seek or gain approval to market its HSV-2 vaccine; whether Vical will fully enroll the Phase 1/2 trial by the fourth quarter of 2014, if at all; and whether topline data will be available by mid-2015; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Andrew Hopkins (858) 646-1127 Website: www.vical.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 54

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 250

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 106

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 82

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 176

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 106

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 103

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 0

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 80

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Gene Therapy Brings Hope to Young Patients

Updated Category News Views 279

Transformative Journey of Gene Therapy for AADC Deficiency Laughter and joy filled the sunny lobby of a research clinic, where a spirited little boy named Sriansh Ojha played happily with his sister, marking a dramatic contrast to his early life struggles. This remarkable transformation is largely due to gene therapy, a groundbreaking treatment that has changed the...

Continue Reading
Damon Inc. Unveils $30 Million Equity Offering for Mobility Innovation

Updated Category News Views 224

Introduction to Damon's Innovative Strategy Damon Inc. has recently announced a substantial $30 million Regulation A+ equity offering, which is set to enhance its impressive lineup of personal mobility products. The company, renowned for its electric motorcycles, aims to leverage the proceeds not only to fuel innovation in its products but also to fortify its...

Continue Reading
Cindy Eckert: Shaping the Future of Women's Health Together

Updated Category News Views 375

Cindy Eckert's Impact on Women's Health Innovation Cindy Eckert, the remarkable Founder and CEO of Sprout Pharmaceuticals, has been announced as the keynote speaker for the highly anticipated Women's Health Summit at Harvard Business School. This significant event, scheduled for 2025, aims to unite leaders, investors, and innovators dedicated to transforming women's...

Continue Reading
VoiceBrain and Diga-Talk Forge Partnership to Enhance Communications

Updated Category News Views 270

VoiceBrain and Diga-Talk Solutions Collaborate for Innovation In a groundbreaking partnership, VoiceBrain, renowned for its AI voice analytics, has teamed up with Diga-Talk Solutions, specialists in Push-to-Talk (PTT) over cellular technology. This exciting collaboration was unveiled during a prominent industry event, aiming to revolutionize real-time communication across...

Continue Reading
AstaReal's Research Reveals Astaxanthin Benefits for Kids' Eyes

Updated Category News Views 234

AstaReal's Groundbreaking Research on Astaxanthin AstaReal, Inc. has made a significant advancement in understanding children's eye health with its innovative research on astaxanthin. This powerful antioxidant, derived from the microalgae Haematococcus pluvialis, has been recognized globally for its benefits in enhancing visual performance, particularly in adults....

Continue Reading